R&D Tax Credits for Biotech Companies
We help biotech companies capture those incentives while maintaining the documentation required to support and defend the claim.
What Sets Us Apart
- California CPA License
- 8+ Years Specialized Experience
- Flat Fee Pricing Model
- Federal & State Credit Expertise
Do Biotech Companies Qualify for R&D Tax Credits?
Biotechnology companies frequently perform activities involving:
- Scientific uncertainty
- Experimental design
- Laboratory testing
- Process development
- Prototype development
- Product optimization
- Clinical and regulatory preparation
These activities often satisfy the requirements under Internal Revenue Code Section 41.
For many biotech businesses, the federal R&D tax credit becomes one of the most valuable non-dilutive funding sources available.
Why Biotech Companies Frequently Qualify
The federal R&D tax credit focuses on four primary tests:
- Technical uncertainty existed.
- A process of experimentation occurred.
- The work was technological in nature.
- The objective was to improve functionality, quality, reliability, or performance.
Most biotechnology development programs naturally involve all four elements.
Examples of Technical Uncertainty
- Will the compound achieve the intended outcome?
- Which formulation performs best?
- Can manufacturing be scaled efficiently?
- Which delivery method is most effective?
- How can efficacy be improved?
- Can adverse reactions be reduced?
- How can sensitivity or specificity be improved?
These questions are rarely answered at the beginning of development.The experimentation required to answer them often creates eligibility for the credit.
Common Qualifying Activities
New Feature Development
Building new product functionality often involves experimentation and uncertainty.
Examples: (Workflow automation, Reporting systems, Collaboration features, User permission systems, Integrations)
Architecture Improvements
Examples: (Microservice migration, Database redesign, Performance optimization, Infrastructure modernization)
Scalability Initiatives
Examples: (Load balancing, Distributed systems, Query optimization, Caching strategies)
Security Enhancements
Examples: (Authentication systems, Encryption methods, Access controls, Compliance architecture)
Artificial Intelligence Features
Examples: Recommendation engines, Predictive models, Classification systems, Natural language processing)
Activities That Usually Do Not Qualify
Examples commonly excluded include:
- Routine quality control testing
- Standard regulatory submissions
- Commercial production activities
- Marketing and sales activities
- Routine data entry
- Administrative functions
Qualification generally depends on whether technical uncertainty and experimentation were present.
Typical Credit Range for Biotech Companies
Credit values vary significantly depending on the size of the research organization and development activity.
Research Team Size | Typical Credit Range |
5–10 Researchers | $50,000–$150,000 |
10–25 Researchers | $150,000–$300,000 |
25–50 Researchers | $300,000–$750,000+ |
Actual results vary depending on qualified expenses and development intensity.
Section 174 and Biotech Companies
Managing both effectively has become increasingly important for biotech CFOs and founders.
Most growing Biotech businesses are affected by both.
Common Mistakes Biotech
Companies Make
Drag to browse
01 / 05
Assuming Their CPA Handles It
Many general accounting firms do not specialize in software R&D credits.
02 / 05
Waiting Until Tax Season
Capturing documentation throughout the year simplifies the process significantly.
03 / 05
Underestimating Qualified Activities
Many companies only include obvious projects and overlook architecture improvements or infrastructure work.
04 / 05
Focusing Only on Federal Credits
State credits often create additional opportunities.
05 / 05
Ignoring Section 174 Requirements
Many startups were caught off guard by the capitalization changes.
Why Biotech Companies Choose Us
CPA-Led Advisory
Led by a California and Nevada CPA with advanced tax specialization.
Flat Fee Pricing
Most providers charge 20-30% of the credit.
We charge a predictable flat fee.
As your credit grows, our fee does not.
Documentation Built for Defensibility
Our goal is not simply maximizing credits.
Our goal is creating supportable and defensible claims.
Defensibility First
We maintain regular communication with founders and technical leaders throughout the engagement.
Long-Term Partnership Approach
Quarterly check-ins improve documentation quality and simplify future filings.
FAQ
Do failed clinical projects qualify?
Yes.
Projects do not need to succeed to qualify for the credit.
Can startup biotech companies qualify?
Absolutely.
Many early-stage biotech companies are ideal candidates.
Do laboratory supplies qualify?
Frequently yes, provided they are consumed during qualified research activities.
Can contract research costs qualify?
In many cases, yes.
Can companies claim credits before profitability?
Yes.
The payroll tax offset may provide immediate benefits.
Does software development within biotech qualify?
Yes.
Bioinformatics platforms and research software frequently qualify.
Vinit Gupta
Brendan Conaway
"You're a BAMF."
What Our Clients Say
Our Clients
